Last updated on May 2017

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy


Brief description of study

This is a double-blind, randomized, placebo-controlled phase 3 non-inferiority study in subjects with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV Non-Small Cell Lung Cancer (NSCLC). Approximately 3000 subjects with stage IV NSCLC expecting to receive at least 2 additional cycles (at least 6 total weeks) of first line myelosuppressive cyclic chemotherapy will be enrolled into the study. Subjects will be randomized in a 2:1 allocation (Group A: darbepoetin alfa 500 µg every 3 weeks , Group B: placebo Q3W)

Detailed Study Description

Oversight Authorities continued: Colombia- pending regulatory approval

Clinical Study Identifier: NCT00858364

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
White River Junction, VT United States
9.92miles
  Connect »